Research

Hormonal

High-dose GLP-1 receptor agonists (e.g., semaglutide 2.4mg) and dual GLP-1/GIP agonists (e.g., tirzepatide) are effective for treating prediabetes by inducing significant weight loss (15-20%), which reduces insulin resistance and lowers diabetes risk.

If you have prediabetes and struggle to lose weight, high-dose GLP-1 or GLP-1/GIP injections (like semaglutide or tirzepatide) are highly effective. They cause significant weight loss (15-20%), which fixes the underlying insulin resistance and reduces diabetes risk. You likely need to stay on them long-term to keep the weight off.

GoodSupportsHIGH confidence
High doses of glucagon-like peptide (GLP)-1 receptor agonists and the combination of a GLP-1 receptor agonist and the glucose-dependent insulinotropic polypeptide (GIP) to lower weight by 15% and 20%, respectively, deserves consideration for the treatment of prediabetes.
Mayer B. Davidson · Diabetes Therapy · 2023

Why this rating

Based on cited RCTs (STEP 1, SURPASS) showing significant weight loss.

Source

Should Prediabetes be Treated Pharmacologically?

Mayer B. Davidson · Diabetes Therapy · 2023

DOI 10.1007/s13300-023-01449-7

narrative_reviewCited 9×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →